Endocrinology and Metabolic Disorders

The European Commission approved Zynquista (sotagliflozin) as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and kidneys absorb and glucose that will result in better diabetes control. Sanofi is collaborating the drug with Lexicon Pharmaceuticals. It has been designed for adults who have a body mass index of 27 kg/m2 and struggle to keep control of their blood sugar levels. A slew of clinical studies was performed on 3,000 people, and the results showed Zynquista helped in decreasing average blood sugar levels, body weight, and blood pressure and improved time wi...